FDA Accepts BMS Protein Degrader for Review; Disc Rare Disease Drug Rejected

Why It Matters

Iberdomide could reshape the multiple myeloma treatment paradigm, while Disc’s setback underscores regulatory rigor for rare‑disease surrogates; Myqorzo and duvakitug signal competitive pressure in cardiology and IBD markets.

Key Takeaways

• BMS iberdomide moves to FDA decision by Aug 17.
• Disc's bitopertin denied accelerated approval over endpoint doubts.
• EU greenlights Cytokinetics Myqorzo, flexible dosing advantage.
• Duvakitug shows 44‑week remission in ulcerative colitis, Crohn’s.
• Merck, Roche advancing TL1A antibodies to Phase 3.

Pulse Analysis

The acceptance of iberdomide marks a pivotal moment for protein‑degrading therapies, or PROTACs, in oncology. By targeting the cereblon E3 ligase, iberdomide adds a novel mechanism to the multiple myeloma armamentarium, potentially overcoming resistance to existing regimens. Analysts view the Aug. 17 decision deadline as a bellwether for how quickly the FDA will endorse next‑generation degraders, a move that could accelerate pipeline investments across biotech firms pursuing similar approaches.

Disc Medicine’s bitopertin rejection highlights the challenges rare‑disease developers face when surrogate biomarkers lack clear clinical correlation. Although the drug lowered protoporphyrin IX, the FDA questioned whether this biochemical change reliably predicts reduced photosensitivity in erythropoietic protoporphyria patients. The outcome serves as a cautionary tale for companies relying on biomarker‑driven accelerated pathways, emphasizing the need for robust, patient‑centric endpoints to satisfy regulators and secure market access.

In Europe, Cytokinetics’ Myqorzo gained approval for obstructive hypertrophic cardiomyopathy, offering clinicians a dosing regimen that does not require genetic testing—a notable advantage over Bristol Myers’ Camzyos. This flexibility could drive broader adoption across the EU’s 27 member states. Simultaneously, Sanofi‑Teva’s duvakitug demonstrated durable efficacy over 44 weeks, positioning it favorably against Merck and Roche’s TL1A antibodies that are still in Phase 3. The long‑term data may accelerate duvakitug’s path to commercialization, intensifying competition in the lucrative IBD therapeutic space.